Standout Papers

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AUR... 2023 2026 202478
  1. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial (2023)
    Juliann Chmielecki, Tony Mok et al. Nature Communications

Immediate Impact

3 from Science/Nature 54 standout
Sub-graph 1 of 22

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Regulatory mechanisms of PD-1/PD-L1 in cancers
2024 Standout
5 intermediate papers

Works of Gianluca Laus being referenced

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
2019
Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
2018
and 1 more

Author Peers

Author Last Decade Papers Cites
Gianluca Laus 616 670 313 26 874
Daisuke Arai 410 499 425 38 807
Junko Hamamoto 441 529 400 27 792
Jih‐Hsiang Lee 658 552 344 36 986
Qi Li 537 564 525 27 1.0k
Osvaldo Rudy Aren 477 629 299 22 818
Francesca Casaluce 505 450 318 37 823
Toshiki Takemoto 518 608 366 39 924
Shinnosuke Ikemura 471 473 489 45 932
Reiko Kaji 780 984 231 44 1.2k
Bethany Pitcher 502 384 326 27 800

All Works

Loading papers...

Rankless by CCL
2026